Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 920-934
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920
Figure 3 Relationship between platelet-to-lymphocyte ratio and treatment response.
A: Difference in platelet-to-lymphocyte ratio according to stable disease and progressive disease; B: Progression-free survival according to the platelet-to-lymphocyte ratio (P < 0.05). PLR: Platelet-to-lymphocyte ratio; PFS: Progression-free survival; SD: Stable disease; PD: Progressive disease.
- Citation: Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934
- URL: https://www.wjgnet.com/1948-5204/full/v14/i4/920.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i4.920